Century Therapeutics, Inc.

IPSC • Biotechnology

$2.11

▲ +0.02 (+0.96%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$434.19M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Crecimiento positivo de ingresos · 141.1%Nivel de deuda manejable · 0.27Liquidez saludable · 5.97Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:21 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$2.11

Change0.96%

Shares Out205.78M

Market Cap$434.19M

Enterprise Value$349.11M

52W Range0.43 - 3.04

Beta1.60

P/E-3.95

P/B1.87

P/FCF-4.98

EV/EBITDA-3.41

EV/FCF-4.00

Price$2.11

Change0.96%

Shares Out205.78M

Market Cap$434.19M

Enterprise Value$349.11M

52W Range0.43 - 3.04

Beta1.60

P/E-3.95

P/B1.87

P/FCF-4.98

EV/EBITDA-3.41

EV/FCF-4.00

Earnings Yield-25.29%

FCF Yield-20.10%

Dividend Yield0.00%

Gross Margin88.00%

Oper. Margin-13.78%

Profit Margin-8.78%

Debt/Eq0.27

Current Ratio5.97

Quick Ratio5.97

Target$2.00

Target Upside-5.21%

Target Median$2.00

Target Range2.00 - 2.00

Volume542.91K

Avg Volume1.18M

EPS Surprise0.04

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

95/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 141.1%Nivel de deuda manejable · 0.27Liquidez saludable · 5.97Rentabilidad débil

Analyst view

Analyst sentiment and price target

IPSC

Analyst sentiment

Based on 9 analyst votes · 2026-09-05

89/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$2.00

Promedio

$2.00

Mediana

$2.00

Alto

$2.00

Resumen de la compañía

IPO: 6/18/2021

Industria: Biotechnology

P/B i: 1.87

Deuda / Patrimonio i: 0.27

Margen operativo: -13.78%

Margen neto: -8.78%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.27

Ratio corriente: 5.97

Ratio rápido: 5.97

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Carr Douglas

Transacción: 08/03/2026

VENTA

Cambio

-275

Precio

$1.98

Presentación

08/05/2026

Tipo

VENTA

Carr Douglas

Transacción: 06/12/2026

VENTA

Cambio

-1,654

Precio

$2.23

Presentación

06/15/2026

Tipo

VENTA

Russotti Gregory

Transacción: 06/12/2026

VENTA

Cambio

-2,584

Precio

$2.23

Presentación

06/15/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Carr Douglas	VENTA	-275	$1.98	08/03/2026	08/05/2026
Carr Douglas	VENTA	-1,654	$2.23	06/12/2026	06/15/2026
Russotti Gregory	VENTA	-2,584	$2.23	06/12/2026	06/15/2026
Cowan Chad	VENTA	-358	$2.24	06/11/2026	06/15/2026
Pfeiffenberger Brent	VENTA	-13,849	$2.24	06/11/2026	06/15/2026
Blackwell Kimberly	COMPRA	+74,000	$2.24	06/11/2026	06/12/2026
Lee Han Myung	COMPRA	+74,000	$2.24	06/11/2026	06/12/2026
Murphy Martin Patrick	COMPRA	+74,000	$2.24	06/11/2026	06/12/2026
Quimi Daphne	COMPRA	+74,000	$2.24	06/11/2026	06/12/2026
Riva Alessandro	COMPRA	+74,000	$2.24	06/11/2026	06/12/2026
Carr Douglas	VENTA	-249	$2.11	06/08/2026	06/09/2026
Russotti Gregory	VENTA	-524	$2.11	06/08/2026	06/09/2026
Pfeiffenberger Brent	VENTA	-463	$2.13	06/05/2026	06/09/2026
Pfeiffenberger Brent	VENTA	-31,172	$2.34	05/15/2026	05/19/2026
Carr Douglas	VENTA	-264	$2.34	05/04/2026	05/06/2026
Murphy Martin Patrick	OTRO	0	Not reported	12/09/2025	04/10/2026
Murphy Martin Patrick	COMPRA	+88,000	$0.59	12/09/2025	04/10/2026
Cowan Chad	VENTA	-1,365	$2.19	04/01/2026	04/03/2026
Russotti Gregory	VENTA	-10,076	$2.55	03/12/2026	03/16/2026
Carr Douglas	VENTA	-7,043	$2.55	03/12/2026	03/16/2026

Sobre la compañía

Century Therapeutics, Inc.

Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.

Fuente - Link

Competidores

COEP CUE EQ GNTA KPTI MDCX OSTX OTLK SNTI TELO

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D Upcoming oral presentations at European Association for the Study of Diabetes (EASD 2026) and Breakthrough T1D® Clinical & Research Congress 2026 highlighting CNTY-813 Company remains on track to advance CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-Evasion™ 5.0 into the clinic this year Cash runway into 1Q 2029 with cash, cash equivalents, and investments of $197.2 million as of June 30, 2026 PHILADELPHIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including T1D, and cancer, today reported financial results for the second quarter ended June 30, 2026, and recent business highlights. "We are executing with speed against key development milestones, reinforcing our confidence in delivering on our ambition to transform diseases like T1D by creating functional cures at scale," said Brent Pfeiffenberger, Pharm.D.

GlobeNewsWire

IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group

ALISO VIEJO, Calif.--(BUSINESS WIRE)--IHI Power Services Corp. (IPSC), a leading operator of power plants across the U.S., has a new name as it enters a new chapter. Effective today, IPSC officially becomes Kyuden Energy Partners Corporation, following the completion of its acquisition by Kyuden International Corporation (Kyuden International), a wholly owned subsidiary of Kyushu Electric Power Company—one of Japan's most powerful electric utilities and a cornerstone of the country's energy inf.

Business Wire

Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026

PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:

GlobeNewsWire

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the presentation of new preclinical data from CNTY-813, Century's iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0, in an oral presentation at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans, Louisiana.

GlobeNewsWire

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical models Allo-Evasion 5. 0 maintains insulin secretion and maintained normoglycemia under allogeneic immune pressure in humanized mouse model without immunosuppression Phase 1 clinical manufacturing process has been established demonstrating consistent endocrine purity and optimal islet cell content CNTY-813 IND submission on track for 4Q 2026; initial clinical data expected in 2H 2027 PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc.

Globe News Wire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-0.15	-0.11	0.04
2026-03-12	-0.28	-0.25	0.03
2025-11-13	-0.39	-0.32	0.07
2025-08-14	-0.38	-0.38	0
2025-05-15	-0.31	0.89	1.2
2025-03-19	-0.45	-0.43	0.02
2024-11-05	-0.46	-0.37	0.09
2024-08-08	-0.5	-0.38	0.12
2024-05-09	-0.5	-0.45	0.05
2024-03-14	-0.56	-0.49	0.07
2023-11-09	-0.53	-0.55	-0.02
2023-08-09	-0.54	-0.56	-0.02